Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;28(7):1486-1490.
doi: 10.1038/s41591-022-01832-0. Epub 2022 Apr 25.

Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years

Ronen Arbel  1   2 , Ruslan Sergienko  3 , Michael Friger  3 , Alon Peretz  4 , Tanya Beckenstein  4 , Shlomit Yaron  4 , Doron Netzer  4 , Ariel Hammerman  4
Affiliations

Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years

Ronen Arbel et al. Nat Med. 2022 Jul.

Abstract

The rapid emergence of the B.1.1.529 (Omicron) variant of SARS-CoV-2 led to a global resurgence of coronavirus disease 2019 (COVID-19). Israeli authorities approved a fourth COVID-19 vaccine dose (second booster) for individuals aged 60 years and over who had received a first booster dose 4 or more months earlier. Evidence for the effectiveness of a second booster dose in reducing hospitalizations and mortality due to COVID-19 is warranted. This retrospective cohort study included all members of Clalit Health Services who were aged 60-100 years and who were eligible for the second booster on 3 January 2022. Hospitalizations and mortality due to COVID-19 in participants who received the second booster were compared with those for participants who received one booster dose. Cox proportional hazards regression models with time-dependent covariates were used to estimate the association between the second booster and hospitalization and death due to COVID-19 while adjusting for demographic factors and coexisting illnesses. A total of 563,465 participants met the eligibility criteria. Of those, 328,597 (58%) received a second booster dose during the 40 day study period. Hospitalization due to COVID-19 occurred in 270 of the second-booster recipients and in 550 participants who received one booster dose (adjusted hazard ratio, 0.36; 95% confidence interval (CI): 0.31-0.43). Death due to COVID-19 occurred in 92 second-booster recipients and in 232 participants who received one booster dose (adjusted hazard ratio, 0.22; 95% CI: 0.17-0.28). This study demonstrates a substantial reduction in hospitalizations and deaths due to COVID-19 conferred by a second booster in Israeli adults aged 60 years and over.

PubMed Disclaimer

References

    1. Burki, T. K. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir. Med. 10, e19 (2022). - DOI
    1. Bar-On, Y. M. et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N. Engl. J. Med. 386, 1712–1720 (2022). - DOI
    1. EU drug regulator expresses doubt on need for fourth booster dose. Reuters (12 January 2022); https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regu...
    1. Hunter, D. J. et al. Addressing vaccine inequity: COVID-19 vaccines as a global public good. N. Engl. J. Med. 386, 1176–1179 (2022). - DOI
    1. Chagla, Z. & Pai, M. COVID-19 boosters in rich nations will delay vaccines for all. Nat. Med. 27, 1659–1660 (2021). - DOI

LinkOut - more resources